The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future

Inflammatory Bowel Diseases

Volumn 23, Issue 10, 2017, Pages 1710-1717

  Allegretti, Jessica ^a,b   Eysenbach, Lindsay M ^c,d   El Nachef, Najwa ^e   Fischer, Monika ^f   Kelly, Colleen ^g   Kassam, Zain ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Open Biome   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

Crohn's disease; fecal microbiota transplantation; inflammatory bowel disease; microbiome; ulcerative colitis

Indexed keywords

GLUTAMATE DEHYDROGENASE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; VEDOLIZUMAB;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; DONOR SELECTION; ENTERIC FEEDING; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS; CLOSTRIDIUM INFECTION; COMPLICATION; FECES; FORECASTING; INTESTINE FLORA; MICROBIOLOGY;

CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FORECASTING; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85029748331     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001247     Document Type: Review

References (43)

1. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508.
2. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109.e6.
3. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-118.e4.
4. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218-1228.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31: 431-455.
6. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
7. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011; 8:17-26.
8. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466-472.
9. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526-536.
10. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: 1443-1450.
11. Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci. 2014;59:2222-2227.
12. Binion DG. Clostridium difficile infection in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012;8:615-617.
13. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4: 589-600.
14. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50-55.
15. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071.
16. Chin SM, Sauk J, Mahabamunuge J, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol. 2017;15:597-599.
17. Newman KM, Rank KM, Vaughn BP, et al. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes. 2017:1-7.
18. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is Safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22: 2402-2409.
19. Crobach MJ, Planche T, Eckert C, et al. European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016; 22(suppl 4):S63-S81.
20. Hashash JG, Binion DG. Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr Gastroenterol Rep. 2014;16:393.
21. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med. 2014;34:787-798.
22. Kassam Z, Lee CH, Yuan Y, et al. Navigating long-term safety in fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1538.
23. Costello SP, Soo W, Bryant RV, et al. Systematic review with metaanalysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213-224.
24. Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and metaanalysis. J Crohns Colitis. [Published online ahead of print May 9, 2017]. doi: 10.1093/ecco-jcc/jjx063.
25. Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 2017;11:1877-1889.
26. Costello S, Waters O, Bryant R, et al. Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mildmoderately active ulcerative colitis: a randomised controlled trial. (FIRSTUC study). European Crohn's and Colitis Organization Confernce. Journal of Crohns and Colitis. Barcelona, Spain: Oral Abstracts, 2017.
27. Osman M, O'Brien K, Stoltzner Z, et al. Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an International Public Stool Bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis. 2016;3(suppl 1):2120.
28. Bajaj J, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rationally selected stool donor is safe, associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy. J Hepatol. 2017;66:S448.
29. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702.
30. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508.
31. Chu ND, Smith MB, Perrotta AR, et al. Profiling Living bacteria informs preparation of fecal microbiota transplantations. PLoS One. 2017;12: e0170922.
32. Suskind DL, Brittnacher MJ, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis. 2015;21:556-563.
33. Eysenbach L, Smith M, Rosenbaum R, et al. Fecal microbiota transplantation as therapy for inflammatory bowel disease. Available at: http://krfoundation. org/krf/site-content/uploads/2016/07/FMT-as-Therapy-for-IBD- Report-For-Publication-revised-6.30.2016.pdf. Accessed May 2017.
34. Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:597-601.
35. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.
36. Fischer M, Sipe B, Cheng YW, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289-302.
37. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-843.
38. Kump PK, Grochenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013; 19:2155-2165.
39. Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10:387-394.
40. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470-476.
41. Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9:309-313.
42. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003;33:244-248.
43. Tedelind S, Westberg F, Kjerrulf M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13: 2826-2832.